GSK ads for Avodart are misleading, says FDA

Share this article:
GSK ads for Avodart are misleading, says FDA
GSK ads for Avodart are misleading, says FDA

Consumer ads in support of GlaxoSmithKline's prostate drug Avodart overstate its efficacy and present misleading claims, the FDA said in a letter to the company.

The specific ad in question—a 60-second TV spot titled Planetarium—depicts artists working on planetary models, with one artist having to leave for the bathroom. Afterward, the actor recounts a conversation with his doctor: "Avodart is different because, over time, it actually shrinks the prostate, so I go less often. Other medicines, they don't treat the cause, because they don't shrink the prostate.”

“The TV ad misleadingly suggests that Avodart is superior to other drug therapies when this has not been demonstrated by substantial evidence or substantial clinical experience,” DDMAC's Cynthia Collins, consumer safety officer, said in the letter, citing Merck's Proscar, another drug approved for the treatment of symptomatic benign prostatic hyperplasia.

FDA also took issue with a graphic showing a large planet and a small planet—used to represent the actor's prostate. “The visual of the planet shrinking in size represents a reduction in prostate volume that is much greater than the reduction actually achieved with Avodart therapy in clinical trials,” the letter said. “In fact, the approximately 20-25% reduction in volume corresponds to a difference in diameter of less than 10%."

The untitled letter requested that GSK immediately cease dissemination of the ad, and submit a written response to the letter by March 4.

Sarah Alspach, a GSK spokesperson, told the Associated Press on Friday that the ad had not aired since last fall, and that GSK “is committed to responsible marketing.”

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.